List of Excipients in Branded Drug BRIVARACETAM

« Back to Dashboard

Generic Drugs Containing BRIVARACETAM

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	brivaracetam	0121-1074	CARBOXYMETHYLCELLULOSE SODIUM
PAI Holdings LLC dba PAI Pharma	brivaracetam	0121-1074	CITRIC ACID
PAI Holdings LLC dba PAI Pharma	brivaracetam	0121-1074	GLYCERIN
PAI Holdings LLC dba PAI Pharma	brivaracetam	0121-1074	METHYLPARABEN
PAI Holdings LLC dba PAI Pharma	brivaracetam	0121-1074	SODIUM CITRATE
PAI Holdings LLC dba PAI Pharma	brivaracetam	0121-1074	SORBITOL SOLUTION
PAI Holdings LLC dba PAI Pharma	brivaracetam	0121-1074	SUCRALOSE

What are the Most Frequently-Used Excipients in BRIVARACETAM?

# Of NDCs	Excipient
4	ACETIC ACID
4	ANHYDROUS CITRIC ACID
7	ANHYDROUS LACTOSE
5	CARBOXYMETHYLCELLULOSE SODIUM
4	CELLULOSE, MICROCRYSTALLINE
1	CITRIC ACID
10	CROSCARMELLOSE SODIUM

Brivaracetam Excipient Strategy and Commercial Opportunities

Last updated: October 3, 2026

Brivaracetam is a small-molecule antiseizure medicine marketed by UCB as Briviact. Its commercial opportunity is concentrated in generic oral dosage forms, pediatric and seizure-rescue formulations, excipient-sensitive products, and differentiated delivery systems. The core tablet is relatively conventional, while the oral solution and intravenous formulation create more meaningful formulation and manufacturing barriers.

What is the formulation profile of brivaracetam?

Brivaracetam is marketed in three principal dosage forms:

Dosage form	Strength	Route	Commercial role
Film-coated tablets	10, 25, 50, 75, 100 mg	Oral	Primary chronic-use product
Oral solution	10 mg/mL	Oral	Pediatric, dysphagia, tube-feeding and dose-flexibility markets
Injection	10 mg/mL	Intravenous	Temporary substitution when oral administration is not feasible

The active pharmaceutical ingredient is brivaracetam, a high-affinity synaptic vesicle protein 2A ligand. The product is approved as adjunctive therapy for partial-onset seizures in patients one month of age and older in the United States. FDA approval covers oral tablets, oral solution and injection presentations. [1]

The tablet formulation uses standard direct-compression or dry-granulation excipient classes: a lactose-containing diluent, microcrystalline cellulose, croscarmellose sodium as disintegrant, povidone as binder, hypromellose and polyethylene glycol as film-coating components, talc, titanium dioxide and colorants. [2]

The oral solution uses a preservative-containing aqueous system with citrate buffering and sucralose-based taste masking. The injection uses an acetate-buffered aqueous vehicle with sodium chloride and water for injection. [3]

What excipients are used in Briviact tablets?

The U.S. tablet label identifies the following inactive-ingredient categories:

Functional purpose	Representative excipient
Dilution and compaction	Lactose monohydrate, silicified microcrystalline cellulose
Disintegration	Croscarmellose sodium
Granulation or binding	Povidone
Film formation	Hypromellose
Plasticization and coating	Macrogol 3350
Glidant and anti-adherent	Talc
Opacification	Titanium dioxide
Color	Iron oxide pigments, depending on strength

The formulation is commercially attractive for generic development because it relies on widely available compendial materials. No unusual lipid system, modified-release polymer, amorphous solid dispersion or device-dependent delivery platform is required for the immediate-release tablet.

The main development risks are process-related rather than ingredient-related. These include:

• Maintaining content uniformity at the 10 mg strength.
• Controlling tablet weight and hardness across the 10 mg to 100 mg range.
• Managing lactose and moisture during granulation and storage.
• Achieving rapid disintegration without capping or friability.
• Matching dissolution across multiple strengths.
• Controlling film-coating color and visual identification.
• Demonstrating bioequivalence with a formulation that differs in excipient level or manufacturing process.

A generic sponsor can generally select alternative suppliers and adjust excipient grades, provided the final product meets quality, dissolution and bioequivalence requirements.

What excipients are used in brivaracetam oral solution?

Briviact oral solution is a 10 mg/mL aqueous formulation. The product uses citrate buffering, a preservative system and an intense sweetener. The principal formulation functions are:

Formulation need	Strategy
pH control	Citric acid and sodium citrate
Microbial preservation	Methyl parahydroxybenzoate, commonly known as methylparaben
Taste masking	Sucralose and flavoring
Vehicle	Purified water or equivalent pharmaceutical-grade water

The oral solution offers the strongest opportunity for excipient differentiation. Pediatric patients may reject bitter or medicinal flavors, and caregivers often administer the product through oral syringes or enteral feeding tubes. A generic sponsor can compete through:

• Improved flavor acceptability.
• A preservative-free presentation.
• A lower-sugar or sugar-free profile.
• Reduced viscosity for tube administration.
• A more stable preservative system.
• A smaller dose volume through a higher concentration, subject to dosing and safety requirements.
• Packaging with oral syringes that improves dose accuracy.
• Child-resistant, senior-friendly closure combinations.
• Unit-dose sachets or stick packs for institutional use.

Taste masking requires more than selecting a sweetener. Brivaracetam’s bitterness, buffering system, preservative level and flavor interaction must be assessed together. Excessive flavor loading can create an aftertaste or reduce long-term stability. The most defensible development program uses sensory testing, pH and preservative challenge testing, extractables and leachables studies, and in-use stability after opening.

What excipients are used in brivaracetam injection?

The injection is a sterile 10 mg/mL solution. Its excipient system is intentionally limited:

• Sodium acetate trihydrate.
• Acetic acid for pH adjustment.
• Sodium chloride for tonicity.
• Water for injection.

The injection has a different commercial profile from the oral products. It is used when oral administration is temporarily unavailable, rather than as the preferred long-term dosage form. The major manufacturing barriers are sterile processing, container-closure integrity, particulate control, endotoxin control and stability.

Commercial differentiation can arise from:

• Ready-to-use premixed bags.
• Low-volume vials or ampoules.
• Compatibility with hospital infusion systems.
• Longer in-use stability after dilution.
• Reduced overfill.
• Improved labeling and dose preparation.
• Lower-cost sterile fill-finish capacity.

A ready-to-administer presentation could reduce pharmacy preparation steps, but it would require a new stability and compatibility package. Any product intended for intravenous infusion must address dilution vehicles, concentration limits, adsorption, precipitation and compatibility with common infusion materials.

What excipient strategy is best for a brivaracetam generic?

The lowest-risk strategy is a conservative tablet formulation that mirrors the reference product’s functional architecture without copying proprietary manufacturing details. A sponsor should prioritize:

1. Compendial excipients with established pharmaceutical supply chains.
2. Lactose-free or low-lactose alternatives only where patient or market demand justifies additional development.
3. A robust low-dose blending process for the 10 mg strength.
4. Rapid dissolution across physiologic pH conditions.
5. Packaging that limits moisture exposure.
6. A manufacturing process that supports all strengths without excessive product-specific changeover.

For the oral solution, the preferred strategy depends on the target market. A U.S. ANDA sponsor may prioritize reference-like composition and straightforward bioequivalence. A specialty manufacturer may pursue a differentiated product with improved taste, preservative positioning or administration convenience.

For injection, the value of excipient innovation is lower than the value of sterile manufacturing reliability. A sponsor with existing hospital injectable infrastructure is better positioned than a tablet-focused company.

How strong is the excipient patent opportunity for brivaracetam?

Excipient patents are unlikely to provide the principal barrier to a conventional brivaracetam generic tablet. The strongest opportunities involve formulation combinations that solve a measurable problem, such as:

• Enhanced aqueous stability.
• Improved taste masking.
• Preservative reduction.
• Reduced injection-site irritation.
• Improved compatibility with enteral feeding tubes.
• Stabilized low-dose powder blends.
• Extended in-use stability.
• A novel multiparticulate or orally disintegrating dosage form.

A patent claim directed only to the use of a common excipient is usually commercially weak unless the claim is tied to a defined concentration range, dissolution profile, stability result or clinical benefit. Claims covering a specific excipient combination and manufacturing process can be stronger, particularly if the formulation is difficult to design around without losing product performance.

The most valuable formulation patents would combine composition and performance limitations. Examples include a defined pH range, preservative concentration, particle-size distribution, dissolution profile, impurity threshold or storage period. Such claims can increase enforcement value, but they also create narrower design-around paths.

When does brivaracetam lose exclusivity?

Brivaracetam is a small molecule, so generic competition proceeds through the ANDA pathway rather than the biosimilar pathway. U.S. exclusivity analysis requires separating FDA regulatory exclusivity from patent protection.

Exclusivity element	Commercial significance
New chemical entity exclusivity	Brivaracetam received FDA approval in 2016; the five-year NCE period has expired
Orphan-drug exclusivity	Not the principal U.S. exclusivity framework for the broad Briviact indication
Pediatric exclusivity	Any applicable six-month extension must be confirmed against FDA records
Listed patents	Can delay approval or launch after ANDA filing
Formulation and method patents	May affect specific dosage forms or labeled uses

The FDA Orange Book remains the controlling source for active U.S. listed patents, expiration dates, pediatric extensions and patent certifications. [4] Brivaracetam’s key commercial exposure is therefore post-NCE generic entry, subject to remaining patent terms and any litigation settlements.

Patent-term calculations must account for patent-term adjustment, patent-term extension, terminal disclaimers and pediatric exclusivity. A nominal 20-year term calculated from a priority date is not sufficient to determine the effective launch date.

What is the Orange Book status of Briviact?

Briviact is listed in the FDA Orange Book as a prescription drug with tablet, oral solution and injection dosage forms. Orange Book patents may cover the active ingredient, specific uses, dosage forms or formulation characteristics. The practical questions for an ANDA sponsor are:

• Which patents are currently listed?
• Which patents expire before or after the target filing date?
• Does each patent require a Paragraph IV certification?
• Does the proposed labeling include the patented method of use?
• Is a section viii statement available for an indication-specific patent?
• Has the reference sponsor filed a timely infringement action?
• Does a 30-month stay apply?

A Paragraph IV notice can trigger litigation if the patent holder brings suit within 45 days. A timely suit can impose a 30-month stay on final ANDA approval, subject to court decisions and statutory exceptions. [5]

Patent risk is different by dosage form. A tablet ANDA may avoid claims specific to the oral solution or injection. Conversely, a sponsor seeking all three dosage forms may face a broader set of formulation and manufacturing issues.

Which companies are challenging brivaracetam exclusivity?

Generic competition is expected to come from companies with established CNS portfolios, ANDA infrastructure and controlled-substance or specialty-pharmacy capabilities. Publicly identifiable challengers should be confirmed through FDA ANDA litigation records, federal court dockets and Orange Book patent-certification data.

The competitive field is likely to include:

• Large generic manufacturers with broad oral-solid capacity.
• Regional companies focused on epilepsy and neurology.
• Specialty manufacturers with pediatric liquid expertise.
• Sterile injectable companies seeking hospital contracts.
• Contract development and manufacturing organizations licensing ready-to-file formulations.

An ANDA filing alone does not establish commercial launch. Litigation, tentative approval, supply agreements and settlement restrictions determine the actual entry date.

What generic launch scenarios exist for brivaracetam?

Early Paragraph IV launch

An early challenger may file with a Paragraph IV certification against remaining listed patents. The commercial upside is substantial if the challenger obtains a favorable judgment or settlement permitting entry before full patent expiry. The risk is litigation cost, a 30-month stay and possible damages exposure.

At-risk launch

An at-risk launch before final patent resolution can capture market share quickly but exposes the sponsor to potential damages and injunctive relief. This strategy is more credible for a tablet-only product with multiple manufacturing sites and a strong patent invalidity or non-infringement position.

Post-expiry launch

A post-expiry launch has lower legal risk but may face entrenched substitution, payer contracting and limited price opportunity. Differentiated oral solution or injection products can preserve margin after tablet commoditization.

Authorized generic or licensed entry

UCB could license manufacturing or distribution rights, or support an authorized generic arrangement. Such deals can reduce litigation exposure while preserving channel control. Public transaction terms should be reviewed in UCB filings and company announcements.

How does brivaracetam compare with levetiracetam?

Brivaracetam competes most directly with levetiracetam, another SV2A-targeting antiseizure drug.

Attribute	Brivaracetam	Levetiracetam
Brand	Briviact	Keppra
Regulatory status	Small molecule, established brand	Broad generic competition
Formulations	Tablet, oral solution, injection	Tablet, oral solution, injection and multiple generic presentations
Market position	Higher-value branded and specialty product	Large generic-volume product
Excipient opportunity	Pediatric liquid, taste, injection and specialty packaging	High-volume cost and supply efficiency
Generic pressure	Increasing after patent and exclusivity erosion	Mature and intense
Commercial strategy	Differentiation and adherence	Lowest sustainable cost

Levetiracetam’s extensive generic competition limits the price that a brivaracetam generic can command. Brivaracetam may retain a premium in hospital, pediatric and neurologist-directed channels if a supplier offers dependable availability or a better-administered liquid product.

What manufacturing and IP barriers affect brivaracetam?

The main barriers are:

• Low-dose content uniformity in tablets.
• Stable, palatable aqueous solution development.
• Sterile injectable production.
• Supply continuity for lactose, polymers, preservatives and coating materials.
• Analytical methods that distinguish active-related impurities and degradation products.
• Device and packaging compatibility.
• Patent clearance for remaining listed claims.
• Reliable commercial-scale validation.

Manufacturing know-how may be more valuable than the excipient list. A generic sponsor that can produce all tablet strengths on one platform, maintain solution stability after opening and provide a validated sterile product can compete more effectively than a sponsor that merely matches the label composition.

What commercial opportunities exist beyond a standard generic?

The strongest opportunities are:

1. A ready-to-use pediatric oral solution with improved flavor and dosing accessories.
2. A preservative-free or lower-preservative liquid where stability and microbiological control support the claim.
3. An orally disintegrating tablet for patients with swallowing difficulty.
4. A sprinkleable multiparticulate formulation, if dose uniformity and stability are demonstrated.
5. A hospital-focused ready-to-administer injection.
6. A dual-source supply agreement for health systems concerned about antiseizure-drug shortages.
7. Geographic licensing in markets where UCB supply is limited or local registration is advantageous.
8. A co-pack containing oral syringes, dosing adapters and caregiver instructions.
9. A manufacturing partnership that combines an oral-solid generic company with a sterile injectable specialist.

The revenue opportunity is highest where formulation differentiation reduces substitution pressure. A conventional tablet generic is likely to compete primarily on price. A pediatric liquid or hospital injectable can compete on availability, usability and procurement reliability.

Key Takeaways

• Brivaracetam has three principal dosage forms: tablets, oral solution and injection.
• The tablet excipient system is conventional and relatively accessible to generic manufacturers.
• The oral solution provides the clearest opportunity for taste, preservative, packaging and pediatric differentiation.
• The injection creates sterile-manufacturing barriers but limited excipient-based differentiation.
• Brivaracetam is subject to small-molecule ANDA competition, not biosimilar competition.
• Remaining patent risk must be assessed through current Orange Book listings, patent certifications and litigation dockets.
• A tablet-only generic is likely to face price competition from levetiracetam and other antiseizure products.
• Specialty liquids, ready-to-administer injectables and reliable supply contracts offer better commercial defensibility.

FAQs

Is brivaracetam a biologic requiring biosimilar approval?

No. Brivaracetam is a chemically synthesized small molecule. Generic versions use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Can a generic brivaracetam use different excipients from Briviact?

Yes. A generic may use different inactive ingredients if the formulation meets FDA requirements, demonstrates pharmaceutical equivalence and bioequivalence, and satisfies safety and labeling requirements.

Does brivaracetam require a preservative in oral solution?

The marketed oral solution uses a preservative system. A preservative-free generic would require suitable packaging, microbiological controls, stability data and regulatory justification.

Which brivaracetam dosage form has the greatest commercial potential?

The oral solution has the greatest formulation differentiation potential. The tablet has the broadest volume opportunity, while the injection is most attractive to companies with established sterile hospital-product infrastructure.

Can an excipient patent block a brivaracetam generic?

It can delay or complicate entry if the patent claims a formulation, manufacturing process or performance profile used by the proposed generic. Common excipient use alone is less likely to create a durable barrier than a narrowly defined, technically supported formulation claim.

References

1. U.S. Food and Drug Administration. (2016). Briviact (brivaracetam) prescribing information.
2. DailyMed. (n.d.). Briviact: Brivaracetam tablet, film coated. U.S. National Library of Medicine.
3. DailyMed. (n.d.). Briviact: Brivaracetam solution and injection. U.S. National Library of Medicine.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Food and Drug Administration. (2022). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs. FDA Guidance for Industry.